China SXT Pharmaceuticals annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals EBITDA Growth & History (SXTC)
China SXT Pharmaceuticals's calculated EBITDA was −$7.0M for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$7.0M | −$4.5M | — |
| 2025 | 2025-03-31 | −$2.6M | −$286,212 | — |
| 2024 | 2024-03-31 | −$2.3M | $3.0M | — |
| 2023 | 2023-03-31 | −$5.4M | −$487,681 | — |
| 2022 | 2022-03-31 | −$4.9M | −$3.0M | — |
| 2021 | 2021-03-31 | −$1.9M | −$842,382 | — |
| 2020 | 2020-03-31 | −$1.0M | −$3.0M | — |
| 2019 | 2019-03-31 | $2.0M | $188,704 | +10.71% |
| 2018 | 2018-03-31 | $1.8M | $60,295 | +3.54% |
| 2017 | 2017-03-31 | $1.7M | — | — |
China SXT Pharmaceuticals quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
China SXT Pharmaceuticals ebitda trends
Over the last five reported fiscal years, China SXT Pharmaceuticals's ebitda decreased from −$1.9M to −$7.0M, a change of −$5.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals filings at SEC.gov ↗